Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC CoronaVac® in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The vaccine is administered intramuscularly in two doses with a 14 to 28-day interval.

The CoronaVac® was previously authorized for emergency use with conditions by the SAHPRA on July 3, 2021. Subsequent to the approval, SINOVAC has been committing to the conditions, reporting the results of ongoing studies and conformance with pharmacovigilance activities as outlined in the approved risk management plan and submitting periodic safety updates. All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.

SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.


Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.

SINOVAC's COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.

SINOVAC was the first company that granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market. SINOVAC looks forward to conducting more extensive and in-depth trade and cooperation with more countries, enterprises, and professional institutions.

For more information, please see the Company's website at www.sinovac.com.

These press releases may also interest you

at 07:35
Gemini Therapeutics, Inc. ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases,...

at 07:30
Think Research Corporation ("Think" or the "Company") a healthcare technology company focused on transforming healthcare through knowledge-based digital health software solutions today announced the results of its August 2, 2022 Annual General...

at 07:30
As per Future Market Insights' latest industry analysis, the global robotic biopsy devices market was valued at around US$ 386.4 Mn in 2021 and is projected to exhibit a CAGR of 9.4% over the forecast period. The...

at 07:30
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda. The milestone acknowledges development of a human...

at 07:30
Biofourmis, a Boston-based global leader in virtual care and digital medicine, today announced that Intel Capital, the strategic investment arm of...

at 07:30
- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival...

News published on 25 june 2022 at 00:35 and distributed by: